Table 1 Patient characteristics of the development and validation cohort
Patient characteristics | Development cohort (n = 107) | Validation cohort (n = 1579) | P-value |
|---|---|---|---|
Age (years), median; IQR | 56.0; 23.0 | 77.0; 17.0 | <  0.001a |
  ≤ 50, n (%) | 38 (35.5) | 94 (6.0) | <  0.001b |
 51–75, n (%) | 60 (56.1) | 646 (40.9) |  |
  ≥ 76, n (%) | 9 (8.4) | 839 (53.1) |  |
Female, n (%) | 46 (43.0) | 731 (46.3) | 0.507b |
Comorbidities, n (%) | |||
 Cardiac comorbidities | 17 (15.9) | 664 (42.1) | <  0.001b |
 Hypertension | 30 (28.0) | 1064 (67.4) | <  0.001b |
 Diabetes Mellitus | 13 (12.1) | 357 (22.6) | 0.011b |
eGFR (MDRD) (≤ 50 ml min−1), n (%) | 9 (8.4) | 439 (27.8) | <  0.001b |
Hypokalemia (<  3.5 mmol L− 1), n (%) | 5 (4.7) | 158 (10.0) | 0.023b |
>  2 QTc-prolonging drugs c, n (%) | 7 (6.5) | 101 (6.4) | 0.953b |
Loop diuretics, n (%) | 23 (21.5) | 400 (25.3) | 0.376b |